In the face of increasing global demand for insulin product, there is a pressing need to develop a more efficient and economical process for the production of recombinant insulin therapeutics. The majority of current recombinant insulin therapeutics are produced from E. coli inclusion bodies, here, we present a new and efficient downstream processing workflow for recombinant human insulin production using E. coli as the host system. New and efficient chromatographic steps were developed for desalting during sample preparation, proinsulin purification and insulin purification, and good purity and recovery were achieved at each step. This new chromatographic process may serve as an excellent chromatographic tool for the purification of recombinant human insulin produced from E. coli inclusion bodies.

New and efficient purification process for recombinant human insulin produced from E. coli inclusion bodies

ACS Fall 2021

The official archive and repository for all ACS Meetings & Expositions abstracts and select posters or presentations.